A major study comparing investigational antibodies to CTLA-4, PD-1, PD-L1, and PD-L-2 found that the combination of anti-PD-L1 and CTLA-4 was the most effective, with a 75% tumor-free survival rate in mice [79]. The gene discussed is PDCD1; the disease is neoplasm.